<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129557</url>
  </required_header>
  <id_info>
    <org_study_id>AAAE0863</org_study_id>
    <secondary_id>#IIRP-906</secondary_id>
    <nct_id>NCT01129557</nct_id>
  </id_info>
  <brief_title>Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease</brief_title>
  <official_title>Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin
      inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to
      conventional ARB therapy (35-45% over 9 months). The investigators hypothesize that
      aldosterone breakthrough occurs due to accumulation of active precursor substances, most
      notably angiotensin II, produced in response to conventional RAAS blockade with ACEinhibitors
      and ARBs. The investigators believe that direct renin inhibition (DRI) should minimize this
      accumulation and therefore significantly lower or possibly eliminate the breakthrough effect.

      Interruption of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting
      enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), alone and in
      combination, has become a leading therapy to slow the progression of chronic heart and kidney
      disease. Both types of drugs inhibit the formation of aldosterone, a hormone, which has been
      shown to have harmful effects on patients with chronic heart and kidney disorders. This
      treatment is effective but not perfect since, even after an initial improvement, many
      patients become worse over the long term. This may be due to an unexpected increase in
      aldosterone, a phenomenon called &quot;aldosterone breakthrough.&quot;

      The purpose of this study is to find out whether the use of a direct renin inhibitor (DRI)
      alone, or in combination with an angiotensin receptor blocker (ARB), will lessen the
      occurrence of aldosterone breakthrough since direct renin inhibitors inhibit the formation of
      aldosterone at a very early step. This study will compare the effectiveness of adding Diovan
      (valsartan) or Tekturna (aliskiren) or a combination of Diovan and Tekturna to the usual
      antihypertensive treatment. The investigators will follow blood pressure, aldosterone levels,
      and urinary protein levels over 9 months to evaluate which of these therapies is most
      effective for treating hypertension in patients with proteinuric kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, three-arm study comparing Diovan (valsartan, an ARB),
      Tekturna (aliskiren, a DRI), and the combination of valsartan + aliskiren (i.e. ARB + DRI).
      One hundred twenty subjects (40 per arm) will be treated with Tekturna, Diovan, or a
      combination of both drugs for 9 months on top of their usual antihypertensive treatment.
      Changes in urinary aldosterone excretion will be monitored during therapy to measure the
      incidence of aldosterone breakthrough, defined as any sustained positive change from baseline
      urinary aldosterone excretion by the completion of the 9-month study period. This frequency
      measure will be compared during ARB, DRI, and ARB + DRI therapy. Changes in urinary protein
      excretion will also be monitored alongside the urinary aldosterone levels to determine
      whether aldosterone breakthrough is associated with refractory proteinuria. This is an
      innovative study that will be the first to (1) examine aldosterone breakthrough during DRI
      therapy, and (2) explore whether addition of a DRI to an ARB protects against aldosterone
      breakthrough. In addition, this will be the first study to examine whether DRI therapy (alone
      or in combination with ARB) is effective therapy for hypertension in patients with
      non-diabetic proteinuric kidney disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.</measure>
    <time_frame>9 months</time_frame>
    <description>The primary outcome of this study is the 9-month cumulative incidence of aldosterone breakthrough, defined as a sustained increase in 24-hour urine aldosterone above baseline, in each treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
    <description>Mean serum aldosterone at baseline, 3-, 6-, and 9-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
    <description>Mean urine aldosterone at baseline, 3-, 6-, and 9-months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
    <description>Mean serum potassium at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour Urine Sodium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
    <description>Mean 24-hour urine sodium (mmol/day) at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment Blood Pressure in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) blood pressure for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment Serum Creatinine in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) serum creatinine for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment Serum Potassium in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) serum potassium for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment 24-hour Urine Protein in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) 24-hour urine protein for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment 24-hour Urine Sodium in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) 24-hour urine sodium for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment 24-urine Aldosterone in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) 24-hour urine aldosterone for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.</measure>
    <time_frame>Baseline and Final (9 month)</time_frame>
    <description>Compares baseline and final (9 month) serum aldosterone for subjects with and without aldosterone breakthrough</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Proteinuric Kidney Disease</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Hypertensive Nephrosclerosis</condition>
  <condition>IgA Nephropathy</condition>
  <condition>Focal Segmental Glomerulosclerosis</condition>
  <condition>Glomerulopathy (Obesity-associated)</condition>
  <condition>Glomerulonephritis, Membranous</condition>
  <arm_group>
    <arm_group_label>Tekturna</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diovan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tekturna &amp; Diovan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily &amp; Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <arm_group_label>Tekturna</arm_group_label>
    <arm_group_label>Tekturna &amp; Diovan</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <arm_group_label>Diovan</arm_group_label>
    <arm_group_label>Tekturna &amp; Diovan</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Proteinuria &gt; 300 mg/day

          -  Normal to mildly reduced kidney function (eGFR &gt; 45 ml/min/1.73m2)

          -  Systolic blood pressure &gt;130 mm Hg

          -  Diastolic blood pressure &gt;70 mm Hg

          -  Diagnoses of diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy,
             focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis,
             membranous nephropathy, fibrillary glomerulonephritis, or obesity-associated
             glomerulopathy

        Exclusion Criteria:

          -  Concomitant use of cyclosporine (which can interact with aliskiren)

          -  Inability to undergo 6 week washout period if already on RAAS-blocking drug(s)
             (includes renin inhibitor, ACE-inhibitor, ARB, and mineralocorticoid receptor blocker)

          -  eGFR &lt; 45 ml/min/1.73m2

          -  Urine protein excretion &lt; 300 mg/day

          -  Serum K &gt; 5.0 mEq/l

          -  Systolic blood pressure &gt; 170 mm Hg or &lt; 130 mm Hg after washout period

          -  Diastolic blood pressure &gt; 110 mm Hg or &lt; 70 mm Hg after washout period

          -  Congestive heart failure NYHA class III and IV

          -  History of any cardiovascular events (stroke, TIA, MI, unstable angina, CABG, PCI, CHF
             hospitalization) in 3 months prior to study visit 1

          -  2nd or 3rd degree heart block without a pacemaker or other uncontrolled arrhythmia

          -  Clinically significant valvular disease

          -  Known renal artery stenosis

          -  Any surgical or medical condition that might significantly alter the pharmacokinetics
             of the study drugs (n.b. bariatric surgery &gt; 6 months prior to visit 1 is not an
             exclusion)

          -  History or evidence of drug or alcohol abuse within the last 12 months

          -  Any concurrent life threatening condition with a life expectancy less than 2 years

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential unless postmenopausal for at least 1 year, surgically
             sterile, or using effective methods of contraception as defined by local health
             authorities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pietro Canetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003.</citation>
    <PMID>22995802</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>February 10, 2014</results_first_submitted>
  <results_first_submitted_qc>April 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2014</results_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Pietro Canetta, MD</investigator_full_name>
    <investigator_title>Instructor in Clinical Medicine, Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
    <mesh_term>Nephrosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diovan</title>
          <description>Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="P2">
          <title>Tekturna</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="P3">
          <title>Tekturna + Diovan</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily for 9 months &amp; Diovan (Valsartan), an angiotensin receptor blocker (ARB) 160 mg by mouth once daily for 9 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Novartis terminated study early</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diovan</title>
          <description>Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="B2">
          <title>Tekturna</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="B3">
          <title>Tekturna+Diovan</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily for 9 months &amp; Diovan (Valsartan), an angiotensin receptor blocker (ARB) 160 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.</title>
        <description>The primary outcome of this study is the 9-month cumulative incidence of aldosterone breakthrough, defined as a sustained increase in 24-hour urine aldosterone above baseline, in each treatment arm.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diovan</title>
            <description>valsartan [angiotensin receptor blocker (ARB)] : Diovan 320 mg PO once daily for 9 months</description>
          </group>
          <group group_id="O2">
            <title>Tekturna</title>
            <description>aliskiren [direct renin inhibitor (DRI)] : Tekturna 300 mg PO once daily for 9 months</description>
          </group>
          <group group_id="O3">
            <title>Tekturna + Diovan</title>
            <description>aliskiren + valsartan (DRI + ARB) : Tekturna 150 mg PO once daily + Diovan 160 mg PO once daily for 9 months</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.</title>
          <description>The primary outcome of this study is the 9-month cumulative incidence of aldosterone breakthrough, defined as a sustained increase in 24-hour urine aldosterone above baseline, in each treatment arm.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Mean serum aldosterone at baseline, 3-, 6-, and 9-months.</description>
        <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>3 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>6 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>9 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O5">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O6">
            <title>3 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O7">
            <title>6 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O8">
            <title>9 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Mean serum aldosterone at baseline, 3-, 6-, and 9-months.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="5.2"/>
                    <measurement group_id="O2" value="4.8" spread="3.1"/>
                    <measurement group_id="O3" value="4.9" spread="3.6"/>
                    <measurement group_id="O4" value="4.9" spread="3.8"/>
                    <measurement group_id="O5" value="7.3" spread="4.5"/>
                    <measurement group_id="O6" value="8.5" spread="4.3"/>
                    <measurement group_id="O7" value="11.7" spread="5.6"/>
                    <measurement group_id="O8" value="11.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Mean urine aldosterone at baseline, 3-, 6-, and 9-months.</description>
        <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>3 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>6 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>9 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O5">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O6">
            <title>3 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O7">
            <title>6 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O8">
            <title>9 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Urine Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Mean urine aldosterone at baseline, 3-, 6-, and 9-months.</description>
          <units>ug/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="9.4"/>
                    <measurement group_id="O2" value="4.4" spread="3.3"/>
                    <measurement group_id="O3" value="5.5" spread="4.3"/>
                    <measurement group_id="O4" value="4.3" spread="2.3"/>
                    <measurement group_id="O5" value="7.4" spread="4.5"/>
                    <measurement group_id="O6" value="11.0" spread="6.2"/>
                    <measurement group_id="O7" value="14.4" spread="8.2"/>
                    <measurement group_id="O8" value="12.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Potassium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Mean serum potassium at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
        <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>3 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>6 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>9 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O5">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O6">
            <title>3 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O7">
            <title>6 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O8">
            <title>9 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Mean serum potassium at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.5"/>
                    <measurement group_id="O2" value="4.4" spread="0.5"/>
                    <measurement group_id="O3" value="4.4" spread="0.4"/>
                    <measurement group_id="O4" value="4.4" spread="0.4"/>
                    <measurement group_id="O5" value="4.3" spread="0.2"/>
                    <measurement group_id="O6" value="4.2" spread="0.2"/>
                    <measurement group_id="O7" value="4.3" spread="0.2"/>
                    <measurement group_id="O8" value="4.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-hour Urine Sodium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Mean 24-hour urine sodium (mmol/day) at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
        <time_frame>Baseline, 3-, 6-, and 9-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>3 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>6 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>9 Months: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O5">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O6">
            <title>3 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O7">
            <title>6 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O8">
            <title>9 Months: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-hour Urine Sodium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Mean 24-hour urine sodium (mmol/day) at baseline, 3-, 6-, and 9-months. (given as reference to interpret contemporaneous plasma &amp; urine aldosterone measurements.)</description>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="67"/>
                    <measurement group_id="O2" value="180" spread="81"/>
                    <measurement group_id="O3" value="188" spread="66"/>
                    <measurement group_id="O4" value="169" spread="70"/>
                    <measurement group_id="O5" value="258" spread="98"/>
                    <measurement group_id="O6" value="220" spread="65"/>
                    <measurement group_id="O7" value="250" spread="102"/>
                    <measurement group_id="O8" value="200" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment Blood Pressure in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) blood pressure for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment Blood Pressure in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) blood pressure for subjects with and without aldosterone breakthrough</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Office systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" spread="10.9"/>
                    <measurement group_id="O2" value="122.0" spread="12.0"/>
                    <measurement group_id="O3" value="136.3" spread="9.8"/>
                    <measurement group_id="O4" value="127.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" spread="8.9"/>
                    <measurement group_id="O2" value="74.0" spread="9.3"/>
                    <measurement group_id="O3" value="87.7" spread="6.6"/>
                    <measurement group_id="O4" value="81.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment Serum Creatinine in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) serum creatinine for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment Serum Creatinine in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) serum creatinine for subjects with and without aldosterone breakthrough</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.3"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                    <measurement group_id="O3" value="1.2" spread="0.5"/>
                    <measurement group_id="O4" value="1.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment Serum Potassium in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) serum potassium for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment Serum Potassium in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) serum potassium for subjects with and without aldosterone breakthrough</description>
          <units>(mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.5"/>
                    <measurement group_id="O2" value="4.4" spread="0.4"/>
                    <measurement group_id="O3" value="4.3" spread="0.2"/>
                    <measurement group_id="O4" value="4.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment 24-hour Urine Protein in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) 24-hour urine protein for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment 24-hour Urine Protein in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) 24-hour urine protein for subjects with and without aldosterone breakthrough</description>
          <units>(mg/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2827" spread="2736"/>
                    <measurement group_id="O2" value="1911" spread="2958"/>
                    <measurement group_id="O3" value="3844" spread="3502"/>
                    <measurement group_id="O4" value="2681" spread="2967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment 24-hour Urine Sodium in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) 24-hour urine sodium for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment 24-hour Urine Sodium in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) 24-hour urine sodium for subjects with and without aldosterone breakthrough</description>
          <units>(mmol/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" spread="67"/>
                    <measurement group_id="O2" value="169" spread="70"/>
                    <measurement group_id="O3" value="258" spread="98"/>
                    <measurement group_id="O4" value="200" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment 24-urine Aldosterone in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) 24-hour urine aldosterone for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment 24-urine Aldosterone in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) 24-hour urine aldosterone for subjects with and without aldosterone breakthrough</description>
          <units>(ug/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="9.4"/>
                    <measurement group_id="O2" value="4.3" spread="2.3"/>
                    <measurement group_id="O3" value="7.4" spread="4.5"/>
                    <measurement group_id="O4" value="12.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.</title>
        <description>Compares baseline and final (9 month) serum aldosterone for subjects with and without aldosterone breakthrough</description>
        <time_frame>Baseline and Final (9 month)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O2">
            <title>Final: Subjects Without Aldosterone Breakthrough</title>
          </group>
          <group group_id="O3">
            <title>Baseline: Subjects With Aldosterone Breakthrough</title>
          </group>
          <group group_id="O4">
            <title>Final: Subjects With Aldosterone Breakthrough</title>
          </group>
        </group_list>
        <measure>
          <title>Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.</title>
          <description>Compares baseline and final (9 month) serum aldosterone for subjects with and without aldosterone breakthrough</description>
          <units>(ng/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="5.2"/>
                    <measurement group_id="O2" value="4.9" spread="3.8"/>
                    <measurement group_id="O3" value="7.3" spread="4.6"/>
                    <measurement group_id="O4" value="11.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tekturna</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="E2">
          <title>Diovan</title>
          <description>Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months</description>
        </group>
        <group group_id="E3">
          <title>Tekturna + Diovan</title>
          <description>Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily for 9 months &amp; Diovan (Valsartan), an angiotensin receptor blocker (ARB) 160 mg by mouth once daily for 9 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>&gt;25% increase in creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Bomback, MD</name_or_title>
      <organization>Columbia University Medical Center, Division of Nephrology</organization>
      <phone>212-305-5020</phone>
      <email>asb68@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

